Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + lazertinib versus osimertinib versus lazertinib in first-line EGFR-mutated advanced or metastatic non-small cell lung cancer
jRCT2080225336Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Amivantamab + lazertinib, Osimertinib + matching placebo and Lazertinib + matching placebo (3 arms). Started Aug 2020; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225336.